{"page":{"totalFilteredElements":39},"studies":[{"active":true,"description":"Prospektive Beobachtungsstudie mit Erstellung einer Biodatenbank zur Untersuchung potentieller Biomarker f&#252;r Risikostratifizierung, Therapiesteuerung und Vertr&#228;glichkeit in Patient*innen mit neuroendokrinen Neoplasien (NENReg)","eudractNumber":null,"id":11499,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"pro","name":"Prostatakrebs"},{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio1","name":"Karzinom der Speiseröhre (Oesophaguskarzinom, inkl. gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno1","name":"Mundhöhlenkarzinom, Rachenkarzinom, inkl. Mundboden- und Zungengrundkarzinom"},{"id":"hno2","name":"Kehlkopfkrebs (Larynxkarzinom)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2025-11-01T09:14:44+01:00","shortTitle":"NENReg","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Multizentrische, l&#228;nder&#252;bergreifende, prospektive, beobachtende Unbedenklichkeitsstudie zur Beschreibung der Inzidenz der Abbruchquote aufgrund von Diarrhoe innerhalb der ersten 3 Monate der Behandlung mit Neratinib bei erwachsenen Brustkrebspatienten als erweiterte adjuvante Behandlung in einem realen Umfeld: die NERLYFE-Studie","eudractNumber":null,"id":9352,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2022-06-10T10:14:43+02:00","shortTitle":"NERLYFE-Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Preoperative radiotherapy versus postoperative radiotherapy after neoadjuuvant chemotherapy (\"NeoRad\") in high-risk breast cancer: a prospective, randomized, international, multicenter Phase III trial","eudractNumber":null,"id":10183,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04261244","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-07-02T13:59:29+02:00","shortTitle":"NeoRad","therapeutical":true,"therapyLines":[{"id":"tl_7","name":"Neoadjuvant"}]},{"active":true,"description":"Treatment and outcome of patients with advanced breast cancer: clinical research platform for real world data (OPAL)&#160;<b>IOM-100361</b>","eudractNumber":null,"id":4638,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"HER2/neu","id":"mt_19"},{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"ER+","id":"mt_47"}],"nctNumber":"NCT03417115","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2018-05-03T12:36:45+02:00","shortTitle":"OPAL (IOM-100361)","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"An Epidemiological, Prospective Cohort Study to Generate Real-world Evidence in Patients with HR*/HER2- Advanced Breast Cancer Treated in the First-line Setting as per Current Standard of Care with an Endocrine-based Palbociclib Combination Therapy","eudractNumber":null,"id":6466,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"HER2/neu","id":"mt_19"},{"name":"CDK (Cyclin-Dependent Kinase)","id":"mt_205"},{"name":"CDK 4/6","id":"mt_26"},{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"ER+","id":"mt_47"},{"name":"PgR (Progesteronrezeptor)","id":"mt_221"},{"name":"PgR+","id":"mt_49"},{"name":"CDK4","id":"mt_131"},{"name":"CDK6","id":"mt_176"}],"nctNumber":"NCT04767594","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2020-11-26T12:01:05+01:00","shortTitle":"PERFORM","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prospektives, akademisches, translationales Forschungs-Netzwerk zur Optimierung der onkologischen Gesundheitsversorgung Qualit&#228;t in der adjuvanten und der fortgeschrittenen/metastasierten Situation: Gesundheitsforschung, Pharmakogenomik, Biomarker, Gesundheits&#246;konomie PRAEGNANT Brustkrebs: Fortgeschritten/ Metastasierend<div><b>VERSORGUNGSFORSCHUNGSSTUDIE</b><br /></div>","eudractNumber":"2014-000854-12","id":4161,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT02338167","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2014-08-26T09:40:07+02:00","shortTitle":"PRAEGNANT Mammakarzinom","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"},{"id":"tl_4","name":"> Drittlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"Evaluation der DIGA consilium care bei Patientinnen mit Her 2 positiven Brustkrebs w&#228;hrend einer Chemotherapie in Kombination mit einer Her 2 zielgerichteten Antik&#246;rper Therapie","eudractNumber":null,"id":8562,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05425550","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2023-06-01T09:40:37+02:00","shortTitle":"PRO2","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Patienten-Typologisierung f&#252;r ein bedarfsgerechtes und effektiveres Coaching bei Patientinnen mit Hormonrezeptor positivem Mammakarzinom / <b>PaTyp</b><div><b><br /></b></div><div><b>VERSORGUNGSFORSCHUNGSSTUDIE</b><b><br /></b></div>","eudractNumber":null,"id":7720,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"PgR (Progesteronrezeptor)","id":"mt_221"},{"name":"ER (Östrogenrezeptor)","id":"mt_248"}],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-03-12T14:28:59+01:00","shortTitle":"PaTyp","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Patienten-Typologisierung f&#252;r ein bedarfsgerechtes und effektiveres Coaching bei Patientinnen mit Hormonrezeptor positiven MammaCa / PaTyp<div><br /></div><div><b>VERSORGUNGSFORSCHUNGSSTUDIE</b></div>","eudractNumber":null,"id":10616,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"PgR (Progesteronrezeptor)","id":"mt_221"},{"name":"ER (Östrogenrezeptor)","id":"mt_248"}],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-03-13T08:39:41+01:00","shortTitle":"PaTyp","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<p class=\"MsoNormal\">Prospektive Beobachtungsstudie molekulares Tumorboard am CCC Mainfranken des Universit&#228;tsklinikums W&#252;rzburg</p>","eudractNumber":null,"id":7637,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn1","name":"Gebärmutterkrebs (Uteruskarzinom)"},{"id":"gyn2","name":"Gebärmutterhalskrebs (Zervixkarzinom)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"pro","name":"Prostatakrebs"},{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro1","name":"Nierenzellkarzinom"},{"id":"uro2","name":"Tumoren der ableitenden Harnwege (Nierenbecken, Ureter, Harnblase, Harnröhre)"},{"id":"uro3","name":"Hodenkarzinom"},{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio1","name":"Karzinom der Speiseröhre (Oesophaguskarzinom, inkl. gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"gio4","name":"Weitere Tumoren des Verdauungstraktes (z.B. Gastrointestinale Stromatumoren, GIST)"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"giu4","name":"Weitere Tumoren des Verdauungstraktes (z.B. Gastrointestinale Stromatumoren, GIST)"},{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno1","name":"Mundhöhlenkarzinom, Rachenkarzinom, inkl. Mundboden- und Zungengrundkarzinom"},{"id":"hno2","name":"Kehlkopfkrebs (Larynxkarzinom)"},{"id":"hno3","name":"Kopf-Hals-Malignome"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"zns","name":"Hirntumore (ZNS Tumore)"},{"id":"zns1","name":"Astrozytäre Gliome (Astrozytom, Glioblastom)"},{"id":"zns2","name":"Meningeom"},{"id":"zns3","name":"Akustikusneurinom (Vestibularis-Schwannom)"},{"id":"zns4","name":"Weitere Hirntumoren"},{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"},{"id":"hau2","name":"Basaliom"},{"id":"hau4","name":"Merkelzellkarzinom"},{"id":"sar","name":"Sarkome"},{"id":"sar1","name":"Knochensarkome (Ewing-Sarkom, Osteosarkom etc.)"},{"id":"sar2","name":"Weichteilsarkome (Liposarkom, Leiomyosarkom, etc.)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"Sequenzierungspanel","id":"mt_58"}],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2022-04-19T14:01:24+02:00","shortTitle":"Prospektive Beobachtungsstudie molekulares Tumorboard am CCC Mainfranken des Universitätsklinikums Würzburg","therapeutical":true,"therapyLines":[]}]}